IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Restless Legs Syndrome
Mayo ClinicSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Restless Legs Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ropinirole GlaxoSmithKline | Phase 4 | A |
FERRIC CATION University of Zurich | Phase 4 | BBB |
VITAMIN D University of Sao Paulo General Hospital | Phase 4 | BB |
Ctc-501 Massachusetts General Hospital | Phase 4 | BB |
Ferumoxytol Auerbach Hematology Oncology Associates P C | Phase 2 | B |
View all 9 →
Same molecule, other indications
IRON(II) SULPHATE (1:1), HEPTAHYDRATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →